Volume 02, Issue 01

A Randomized Controlled Trial of Blister Graft (Epidermal Grafting) versus Split-thickness Skin Grafting (STSG) in Wound Healing our Experience

Abhishek Sharma

Corresponding Author: Abhishek Sharma, MS. MCh., Senior Consultant, Director and Head Dept of Plastic Surgery, All Is Well Mult Speciality Hospital Burhanpur, Madhya Pradesh, India. Email: drabhisheksharma7@gmail.com.

Abstract

Background A skin graft is a surgical procedure that involves removing healthy skin from one area of the body to another. Spl itthickness skin grafting (STSG) is one of the basic modalities for wound cover. [1] Sometimes the donor site becomes painful and leaves a second wound or scar, which may take longer to cure than the primary graft site itself. Blister graft or suction graft (Epidermal grafting) is an alternative method of skin grafting in which we apply continuous negative pressure to the skin to harvest the epidermal layer of the skin. This procedure leaves minimal donor site morbidity or scars and is relatively less painful. It can be done on an outpatient basis. In our study, we try to compare the Blister graft (epidermal graft) with split-thickness skin grafting (STSG) and the mechanisms by which each technique achieves wound healing.

Keywords: Skin Graft • Split-Thickness Skin Grafting • Blister Graft

Introduction

Blister graft Epidermal grafting for wound healing is not a new concept, and several case reports have reported a good wound healing outcome; however, it is not known if the healing rate is comparable to split thickness skin rafting, a mainstay of treatment for wounds that cannot be closed primarily [1-5]. This study is to investigate the efficacy of epidermal grafts against split-thickness skin grafts. We hypothesize that epidermal grafts have the same wound-healing outcome as split-thickness skin grafts but with a lower donor site morbidity. In this trial design, we try to evaluate the wound-healing mechanism of epidermal grafts and split-thickness skin grafts to promote further understanding and compare the mechanisms of healing at the cellular level. It is postulated that epidermal grafting stimulates wound healing by acting like bioengineered skin by expressing growth factors, thereby encouraging the wound bed to regenerate, and by initiating keratinocyte migration from the edges of the wound [5-11]. In vitro studies showed that the migrating keratinocytes from the grafts synthesize several growth factors, namely the vascular endothelial growth factor, hepatocyte growth factor, granulocyte colony-stimulating factor, platelet-derived growth factor, and transforming growth factor a [10,12]. The migrating keratinocytes also deposit a variety of extracellular matrix components, such as laminin, fibronectin, and type IV collagen [5,10,12]. The wound exudate analysis in this trial demonstrated the expression pattern of the growth factors expressed by the grafts in vivo [11]. The effect of the growth factors on the wound bed and the edges of the wound

is further confirmed by the punch biopsies. The punch biopsy taken from the canter of the wound was used to identify the expression pattern of the keratinocyte and other markers of proliferation before and after treatment, which could suggest the activation of the wound bed with treatment. The skin biopsy from the wound edges is used to study the migratory activity of the keratinocytes by determining the expression pattern of the connexin proteins [5,10.11]. The Connexin proteins are gap junctional proteins, which are channel-forming proteins that enable adjacent cells to communicate and play a vital role in coordinating cell proliferation and migration [11]. It is known that the downregulation of Connexin protein at the edges of the wound correlates with increased keratinocyte migratory activity, resulting in accelerated wound healing [12]. As the epidermal graft is postulated to stimulate the keratinocytes at the wound edges [5]. This, in turn, indicates that the keratinocytes have increased migratory properties. This will also be correlated with the proliferation markers of keratinocytes [11]. This study is expected to define the efficacy of blister graft (epidermal grafting) and further understand the mechanism of wound healing by epidermal grafting compared to split-thickness skin grafting. These results can be used further to enhance the current best practice for wound care.

Materials and Methods

This study was conducted in our centre. In our study, we compare the efficacy and wound-healing mechanisms of blister grafts (epidermal grafts) with split-thickness skin grafts. The primary outcome measures are the proportion of wounds healed in 6 weeks and the donor site healing time. The secondary outcome measures include the mean time for complete wound healing, pain score, patient satisfaction, health care utilization, cost analysis, and incidence of adverse events. [13]. Study design: This study is a randomized control trial that includes 26 patients in two parallel groups. Eligible patients are randomized to blister grafting or split-thickness skin grafting using a computerized randomization method. Participants were admitted to our hospital from March 2021 to March 2023. Eligibility criteria: Patients who visited our department (plastic and cosmetic surgery) for skin grafting were eligible for this study. During enrolment, patients are subjected to screening for inclusion in the trial and a patient information sheet is given to each of them explaining the aims, techniques of skin grafting and subsequent wound management, anticipated benefits, and potential risks of the procedure. Patients are given sufficient time to decide whether they wish to participate. Informed consent was obtained. Treatment was given within a week of patient enrolment. [1,3,4].

Inclusion criteria are as follows:

- 1. Age \geq 14 years
- 2. Wound measuring > 2 cm x 2 cm and less than 20 cm
- 3. Clean, healthy granulating bed

4. All patients were explained to understand and be willing to participate in the study and be able to comply with the weekly visits and follow-ups.

Exclusion criteria are as follows:

1. Infected wound

- 2. Wound at the plantar aspect of the foot
- 3. Not suitable for split-thickness skin grafting

4. Previous history of excessive bleeding associated with trauma, surgical procedure, or co-morbid medical conditions, including hepatic, renal, and active autoimmune diseases

5. Uncontrolled diabetes mellitus (as measured by HbA1c \ge 8%)

6. Pre-immune or immune disease, hematologic diseases7. Use of a systemic steroid or immunosuppressant8. I am not fit for surgery

Interventions

Wound bed preparation: All wounds are prepared as per guidelines of normal clinical practice, which is either using appropriate wound dressings or negative pressure wound therapy (NPWT) to achieve a healthy granulating wound. [7,9] Wound swabs are used to rule out any bacterial infection or bacterial growth. During the preparation of the wound bed, the patient was referred to our research team. When the bed is ready for the procedure, patients are then screened and offered a patient information sheet for inclusion in the trial. Once the patients were ready for intervention, informed consent was obtained.

Blister Graft (Epidermal Graft)

Before the grafting procedure, the wounds are cleaned using a normal saline solution by the surgeon and debrided if required. The 50- and 20-cc syringes are applied in reverse direction over the epidermal graft area to be harvested, and the mouths of the syringes are fixed with another syringe through a silicon tube, and negative suction is maintained for 30 to 40 minutes.[2] The harvested epidermal grafts are then transferred onto the wound using a non-adhering silicone dressing. The wound is then dressed with NPWT or gauze, whichever is deemed appropriate based on the type of wound. [7,9] The dressing is then secured with a crepe bandage, and the use of Tegaderm is considered for wounds that are more exudative or have had previous infections. The wound and donor site was reviewed after a week post-grafting.



Figure 1. Blister graft (epidermal graft harvesting).

Split-Thickness Skin Graft

Patients underwent this procedure in the operating room under general or local anesthesia. The wound was debrided initially in a similar manner to the epidermal graft group. Skin is harvested from the thigh using a skin grafting knife and meshed by 1:1.5 and 1:2 ratios. The wound is then grafted and Patients underwent this procedure in the operating room under general or local anesthesia. The wound was debrided initially in a similar manner to the epidermal graft group. Skin is harvested from the thigh using a skin grafting knife and meshed by 1:1.5 and 1:2 ratios. The wound was debrided initially in a similar manner to the epidermal graft group. Skin is harvested from the thigh using a skin grafting knife and meshed by 1:1.5 and 1:2 ratios. The wound is then grafted and dressed with gauze and a Medpore or crepe bandage, depending on the site of the graft. The donor site is dressed with Alginate dressing 3 cm beyond the wound margins and secured with adhesive tape as per standard clinical practice, the grafts are checked after a week.



Figure 2. Split-thickness, Skin grafting.

Blister Graft (Epidermal Graft)

Wound exudate sampling and biopsy: Wound exudate sampling was performed by applying a filter paper to the wound for 1 to 20 minutes until it was absorbing enough exudates and became moist. The filter paper is then stored in a sterile vial and transferred to the laboratory. The wound fluid sampling is performed before skin grafting and at each review or after 7 days. After administering adequate local anesthesia (2% lidocaine), Skin punch biopsies (5 mm) are taken from two locations, one at the center of the wound and the other at the wound edge. This procedure is done before skin grafting and repeated after a week post-grafting. The specimens are then placed in a sterile vial containing 4 percent paraformaldehyde and sent to the laboratory.

Laboratory Studies Methodology Summary is as Follows:

1. The wound exudate samples are used to determine the pre-grafting and post-grafting concentrations of different types of growth factors using an enzyme-linked immunosorbent assay (ELISA) [10,11].

2. The skin biopsies are used to compare the pattern of expression of keratinocyte proliferative markers and Connexin protein (gap junctional proteins) before and after skin grafting at the wound edge and the wound center. Tissues are cryo-sectioned and stained with hematoxylin and eosin (H&E) and analyzed for immunohistochemistry [11].

Study Outcome

Most of the wounds, or their proportion, were healed completely at 6 weeks post-grafting, and the time for donor-site healing varies from two weeks to 6 weeks. Complete wound healing is defined as 100% re-epithelialization [8] The assessment of wound healing was done through wound measurement at each review. The photographs of the wounds and the donor sites were taken at each weekly visit using a high-quality camera with accurate and standardized images for digital measurement of the wound surface area and angiogenesis [8] These images were stored in the patient's digital photo diary. An independent, blinded analysis of the photo diary was carried out by us from time to time. The secondary endpoints were the pain score mean time for complete wound healing, as noted by patients' complaints using a numerical rating scale (0–10), and patient satisfaction measured by using a validated patient questionnaire related to their satisfaction. [1,3] Cost analysis of healthcare utilization is measured by the consumable items used, the incidence of adverse events, and the frequency of visits. [13] The incidence of adverse events includes mortality of any cause within the 3-month duration from the time of initial therapy [1,3] The incidence of wound-related adverse events (WAEs), and the incidence of device-related adverse events (DAEs) occurring within the study duration. The patient questionnaire related to skin

graft satisfaction was completed by the participants at the 6-week and 3-month visits [1]Furthermore, we determined the mechanism of wound-healing of blister grafting compared to STSG by analysing the type and concentration of growth factors expressed by the grafts, as well as the expression of Connexin proteins (gap junctional protein) and keratinocyte proliferative markers at the wound edge and the center of the wound before and after grafting [5,12]Participant timeline the study was conducted between March 2021 and March 2023. Each patient is followed up weekly for one and a half months or until the wound heals. The final follow-up was at the end of the third month from the initiation of the treatment. In the event of failure of the primary intervention within 6 weeks, regrafting and a repeat biopsy were performed as per protocol after discussion with the patient. Failed intervention is defined as increasing wound size or failure of 50% reduction in wound size at week 6 or more [1,3].

Brief Study Protocol of Patient's Journey

1. Patients were referred by various hospitals to our centre.

- 2. Wound bed preparation is done.
- 3. Patient screening is done, and a patient information leaflet is given to them.
- 4. Patient consent for the procedure and enrolment done.
- 5. Patients were randomly distributed (n = 13) for blister grafting and (n = 13) for split-thickness skin grafting.
- 6. The patient underwent wound exudate sampling, and 5 mm punch biopsies samples were sent to the laboratory. followed by procedures.
- 7. Patient reviews after a week for sampling and biopsy.
- 8. The patient followed up weekly for 6 weeks.
- 9. The last and final review is at the end of 12 weeks.

Sample Size

Our study revealed that both techniques offer the same healing rate after a 6-week post-grafting procedure; however, donor site morbidity is present in 38% of the patients with split-thickness skin grafts, while only 4% is seen in patients with blister grafts. The morbidity of the donor site includes discoloration, pain, scarring, and the risk of infection. Given a significance level of 0.045 for 70% power, a sample size of 13 patients per group is obtained. In consideration of a potential dropout rate of 14%, adjustments have been made to the sample size, with an increase to 16 patients per treatment arm. A total of 26 patients were recruited for the study. The timeline for recruitment was 24 months.

Randomization, Allocation Concealment, and Blinding

After obtaining consent, patients are randomly assigned to one of the treatment groups. A random allocation sequence is computergenerated. The allocation sequence is sealed in identical envelopes and given to the enrolling investigator upon receipt of patient consent. None of the surgical team members, clinical staff, or patients are blinded to the intervention status.

Data Collection and Management

All data collected is recorded on paper and digitally. Data collected by the surgical team. Accuracy of the data collection and sample assessments done at regular intervals. Any adverse events are recorded and reported to the primary investigators and the ethical committee. Wounds are assessed and recorded in a wound assessment form at each follow-up visit. Data related to patients' co-morbidities, wound duration, and type, and previous wound bed preparation methods are recorded. The photographs are used to measure the wound surface area digitally. The cost and number of outpatient visits are recorded, and the cost and type of dressings used are documented [1,13].

Data Storage

The data extracted for this study is anonymized. All personal data extracted is stored on the computers, which are password-protected to avoid unauthorized access by unauthorized individuals. Access to the computers is via a secure login.

Statistical Analysis

Patients are assessed for analysis if they received treatment during the study. If the clinical course cannot be fully evaluated, the last point of the visit is considered the last data analyzed. [1,3] Baseline characteristics of both groups are recorded. The categorical variables are compared using Pearson's chi-square, depending on the number of events. The proportion of wounds healed with each treatment is compared using a chi-square test, depending on the number of events. The mean time to wound healing was determined based on the number of days until complete re-epithelialization. Secondary outcomes are compared using a Mann-Whitney U test. A p-value of less than 0.05 will be considered significant [1,3] and all tests will be two-sided.

Discussion

This study defines the efficacy of blister graft and encourages further understanding of the mechanism of wound healing by blister graft (epidermal grafting) compared to split-thickness skin graft. The results of this study could be used to make people aware of the current best practices for wound care. Split-thickness skin grafting (STSG) is a current basic standard of care for wound cover for non-healing wounds. STSG involves the excision of the epidermis and part of the dermis, leaving behind the reticular dermis at the donor site. which enables the skin to heal by secondary intention [1, 8] Despite STSG being an important modality for wound closure, the donor site leaves a second, often painful wound, which may take more time to heal than the graft site itself and holds the risk of infection and scarring [6].



Figure 3. Blister (epidermal) grafting forehead

Sample size

Blister graft is an emerging and promising option to overcome these challenges. Blister grafting is a method of autologous skin grafting that harvests only the epidermal layer of the skin from the donor site by applying gentle heat and continuous negative pressure to the normal skin to raise blisters [2] The roof of the blister, which is the epidermis, is then excised and transferred onto the wound. As the dermis at the donor site remains untouched, the skin regenerates itself without scarring. This procedure also causes less pain as the pain fibres in the dermis are unstimulated, allowing autologous skin grafting in an outpatient setting without the need for local anesthesia [2].



Figure 4. Blister grafting neck.

This study evaluates the efficacy of blister grafts using syringes to create negative pressure. This study was carried out in our center using the method we described. Epidermal grafts are observed to be an effective method of autologous skin grafting, with complete wound healing achieved in two-thirds of selected patients with minimal or no pain and a scar-free donor site.[2,6] The ability to perform epidermal grafting in outpatient settings eliminates the need for an operation theatre and a hospital stay, and it has better patient satisfaction. [6] However, it is not known if epidermal grafting is an effective clinical alternative to split-thickness skin grafting. [6] The mechanism of wound healing by blister graft may be different compared to split-thickness skin grafting, and blister (epidermal) grafting is postulated to promote wound healing by expressing growth factors that accelerate wound healing and encourage keratinocytes to migrate from the wound edge [10,12].



Figure 5. Donor site scarring after STSG.



Figure 6. Donor site scarring after blister (epidermal) grafting.

We observed that epidermal grafting has similar wound healing rates to split-thickness skin grafting at 6 weeks, but with minimal donor site morbidity [3] We wish to promote the importance of epidermal grafts as an alternative to split-thickness skin grafting and to further investigate the mechanisms by which each technique achieves wound healing.

Statement and Declaration

Funding

The author declares that no funds, grants, or other support were received during the preparation of this manuscript.

Competing Interests

The author has no relevant financial or non-financial interests to disclose.

Consent to Participate

Written and informed consent is obtained from all the participants for their participation in this study, the publication of this study article, and the images depicted in the figures.

Ethics approval

The author declares that all the data is presented clearly, honestly, and without fabrication, falsification, or inappropriate data manipulation. Proper acknowledgement of other works is given. The manuscript was created in accordance with the Declaration of Helsinki and the ethical standards of the local ethical committee of the institution (AIWH) with project identification number 2023/714.

Contributor's Information and Affiliation

The author has contributed to the concept, design, analysis and interpretation of this manuscript. The author read and approved the final manuscript.

References

- 1. Kanapathy, Muholan, et al. "Epidermal grafting versus split-thickness skin grafting for wound healing (EPIGRAAFT): study protocol for a randomised controlled trial." Trials 17 (2016): 1-6.
- 2. Gabriel, Allen, Rachel V. Sobota, and Manish Champaneria. "Initial experience with a new epidermal harvesting system: overview of epidermal grafting and case series." Surgical Technology International 25 (2014): 55-61.
- 3. Chan, An-Wen, et al. "SPIRIT 2013: new guidance for content of clinical trial protocols." The Lancet 381.9861 (2013): 91-92.
- 4. Hachach-Haram, Nadine, et al. "The use of epidermal grafting for the management of acute wounds in the outpatient setting." Journal of Plastic, Reconstructive & Aesthetic Surgery 68.9 (2015): 1317-1318.
- 5. Sutcliffe, J. E. S., et al. "Abnormal connexin expression in human chronic wounds." British Journal of Dermatology 173.5 (2015): 1205-1215.
- 6. Hansen, E. L. E., et al. "The psychological impact of split-thickness skin grafts." journal of wound care 21.10 (2012): 490-497.
- 7. Petkar, Kiran, Prema Dhanraj, and H. Sreekar. "Vacuum closure as a skin-graft dressing: a comparison against conventional dressing." European Journal of Plastic Surgery 35 (2012): 579-584.
- 8. Smahel, J. "Revascularization of a free skin autograft." Acta chirurgiae plasticae 4 (1962): 102-112.
- 9. Kim, Eun Key, and Joon Pio Hong. "Efficacy of negative pressure therapy to enhance take of 1-stage allodermis and a split-thickness graft." Annals of plastic surgery 58.5 (2007): 536-540.
- 10. Barrandon, Yann, and Howard Green. "Cell migration is essential for sustained growth of keratinocyte colonies: the roles of transforming growth factor-α and epidermal growth factor." Cell 50.7 (1987): 1131-1137.

- 11. Osborne, Sandra N., et al. "Epidermal micrografts produced via an automated and minimally invasive tool form at the dermal/epidermal junction and contain proliferative cells that secrete wound healing growth factors." Advances in skin & wound care 28.9 (2015): 397-405.
- 12. Kirfel, G., and V. Herzog. "Migration of epidermal keratinocytes: mechanisms, regulation, and biological significance." Protoplasma 223 (2004): 67-78.
- 13. Phillips, Ceri J., et al. "Estimating the costs associated with the management of patients with chronic wounds using linked routine data." International wound journal 13.6 (2016): 1193-1197.